Compositions and methods for vaccinating against HSV-2

Details Compositions and methods for vaccinating against HSV-2 Compositions and methods for vaccinating against HSV-2

2011-05-03

2011-05-03

Salimi, Ali R. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C435S006120, C435S091100

Reexamination Certificate

active

07935352

ABSTRACT:
This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method.

REFERENCES:
patent: 5641665 (1997-06-01), Hobart et al.
patent: 5654174 (1997-08-01), Cohen et al.
patent: 6147055 (2000-11-01), Hobart et al.
patent: 6375952 (2002-04-01), Koelle et al.
patent: 6399588 (2002-06-01), Hobart et al.
patent: 6413518 (2002-07-01), Koelle et al.
patent: 6814969 (2004-11-01), Koelle et al.
patent: 6855317 (2005-02-01), Koelle et al.
patent: 7037509 (2006-05-01), Koelle et al.
patent: 7078041 (2006-07-01), Koelle et al.
patent: 7628993 (2009-12-01), Vilalta et al.
patent: 2003/0203863 (2003-10-01), Hobart et al.
patent: 2005/0065107 (2005-03-01), Hobart et al.
patent: 2005/0163794 (2005-07-01), Koelle et al.
patent: 2006/0024670 (2006-02-01), Luke et al.
patent: 2006/0216304 (2006-09-01), Koelle et al.
patent: 2007/0026015 (2007-02-01), Braun et al.
patent: 2007/0105193 (2007-05-01), Vilalta et al.
patent: 2007/0286869 (2007-12-01), Luke et al.
patent: 2008/0057080 (2008-03-01), Luke et al.
patent: 2008/0102087 (2008-05-01), Vilalta et al.
patent: 2009/0004203 (2009-01-01), Vilalta et al.
patent: WO 00/57917 (2000-10-01), None
patent: WO 01/32221 (2001-05-01), None
patent: WO 03/104400 (2003-12-01), None
Dong et al., “Cellular and Humoral Immune Responses to HSV-2 Tegument Proteins in H-2D Mice after DNA Vaccination,”31st International Herpesvirus Workshop, Seattle, WA (2006), Abstract 9.16.
Ferrari et al., “Synergy between Cationic Lipid and Co-Lipid Determines the Macroscopic Structure and Transfection Activity of Lipoplexes,”Nucleic Acids Research(2002), 30(8):1808-1816, Oxford University Press.
Koelle et al., “Immunogenicity and Protective Efficacy of Plasmid DNA Vaccines Encoding HSV-2 Tegument Proteins in a Murine Intravaginal Challenge Model,”17th International Society of Sexually Transmitted Diseases Research(ISSTDR), Seattle, Washington (2007), Abstract 317.
Muller et al., “Cellular and Humoral Immune Responses Induced by Plasmid DNA Vaccines Encoding HSV-2 Tegument Proteins,”44th Annual Meeting of the Infectious Diseases Society of America(IDSA), Toronto, Canada (2006), Abstract 615, p. 166.
Muller et al., “HSV-2 Tegument Directed T-Cells Develop after Vaginal Infection in Balb/c Mice and Tegument-Based Vaccines Partially Protect against Lethal Challenge,”32nd International Herpesvirus Workshop, Asheville, North Carolina (2007), Abstract 10.20.
Nakamura et al., “Codon Usage Tabulated from International DNA Sequence Databases: Status for the Year 2000,”Nucleic Acids Research(2000) 28(1):292, Oxford University Press.

Affiliated with

Also associated with

Rating

Compositions and methods for vaccinating against HSV-2 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for vaccinating against HSV-2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for vaccinating against HSV-2 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2677329